SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : INCR -- Incara Pharmaceuticals
INCR 1.140-5.0%Dec 24 12:55 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (183)9/25/2002 9:40:57 PM
From: mopgcw   of 196
 
Incara Stock Moves to OTC Bulletin Board Market

PR Newswire, Wednesday, September 25, 2002 at 10:46


RESEARCH TRIANGLE PARK, N.C., Sep 25, 2002 /PRNewswire-Firstcall via COMTEX/ -- Incara Pharmaceuticals Corporation (OTC Bulletin Board: INCR) today announced that it has been informed that its common stock does not meet the requirements for continued listing for the Nasdaq National Market and will begin trading on the OTC Bulletin Board under its current symbol"INCR."The OTC Bulletin Board(R) (www.otcbb.com) is a regulated quotation service that displays quotes, last-sale prices, and volume information in over-the-counter (OTC) equity securities. An OTC equity security generally is any equity that is not listed or traded on Nasdaq(R) or a national securities exchange. OTCBB securities include national, regional, and foreign equity issues, warrants, units, American Depositary Receipts (ADRs), and Direct Participation Programs (DPPs).

Incara Pharmaceuticals Corporation (www.incara.com) is focused on disease therapies based on tissue protection, repair and regeneration. The company is developing a series of catalytic antioxidants as treatments for protection from damage occurring in cancer radiation therapy and stroke and for protection of cells in transplantation. Incara has received allowance of an Investigational New Drug Application (IND) to begin Phase 1 clinical trials of cryopreserved human liver cells for the treatment of patients with cirrhosis and end-stage liver disease.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext